<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180464</url>
  </required_header>
  <id_info>
    <org_study_id>H 553 000- 1309</org_study_id>
    <secondary_id>2013-003757-22</secondary_id>
    <nct_id>NCT02180464</nct_id>
  </id_info>
  <brief_title>A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis</brief_title>
  <acronym>Left/Right</acronym>
  <official_title>A Phase IIa, 28-day Treatment, Multi-center, Randomized, Comparator-controlled, Observer-blind Trial With Intra-individual Left/Right Comparison to Investigate the Anti-psoriatic Efficacy and the Safety of an LAS41004 Formulation in Comparison to an Active Reference in Patients With Mild to Moderate Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof-of concept study to competitively investigate antipsoriatic efficacy and safety of a
      LAS41004 formulation vs active control No formal study hypothesis, but descriptive evaluation
      (PoC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total symptom score</measure>
    <time_frame>day 28 vs baseline</time_frame>
    <description>The primary variable is the TSS. The TSS is calculated by summarizing the individual scores for erythema, scaling and infiltration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total symtom score (during study performance)</measure>
    <time_frame>Days 4, 8, 15, and 22</time_frame>
    <description>Change from baseline in the TSS of each treated plaque on Days 4, 8, 15, and 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment (PGA)</measure>
    <time_frame>Days 1, 4, 8, 15, 22 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global tolerability assessment (PGTA)</measure>
    <time_frame>4, 8, 15, 22 and 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>LAS41004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of approximately 2 - 6 mg/cm2 to an area of 20 - 300 cm2, each once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical application of approximately 2 - 6 mg/cm2 of IMPs 1 and 2 to an area of 20 - 300 cm2, each once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41004</intervention_name>
    <arm_group_label>LAS41004</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control</intervention_name>
    <arm_group_label>LAS41004</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (main):

          -  mild to moderate stable chronic plaque-type psoriasis with at least two symmetrical
             lesions with a treatment area of 20 - 300 cm² and a TSS of ≥ 6;

               -  female volunteers of childbearing potential* must agree to use appropriate and
                  reliable methods of contraception

               -  written informed consent obtained.

        Exclusion Criteria (main):

          -  severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis,

          -  treatment with any locally acting medications which might counter or influence the
             trial aim within 2 weeks preceding the treatment phase of the trial and during the
             trial;

          -  treatment with any systemic medications which might counter or influence the trial aim
             or phototherapy/PUVA within 4 weeks preceding the treatment phase of the trial and
             during the trial;

          -  treatment with vitamin A supplements;

          -  treatment with any biologics within 3 months preceding the treatment phase of the
             trial and during the trial, or in the case of ustekinumab, within 6 months;

          -  treatment with any immunosuppressive medication within 6 months preceding the
             treatment phase of the trial and during the trial;

          -  known allergic reactions, irritations or hypersensitivity to the active ingredients

          -  contraindications according to summary of product characteristics (SmPC) of the active
             comparator: - pregnancy or nursing;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Wigger-Alberti, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>bioskin, Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis, topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

